1018326-11-8

Basic information

• Product Name: 4-(4-(2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperidin-1-yl)-2-methoxybenzonitrile
• Synonyms: 4-(4-(2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperidin-1-yl)-2-methoxybenzonitrile
• CAS NO: 1018326-11-8
• Molecular Weight: 440.853
• Mol File: 1018326-11-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(4-(2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperidin-1-yl)-2-methoxybenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperidin-1-yl)-2-methoxybenzonitrile(1018326-11-8)
• EPA Substance Registry System: 4-(4-(2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperidin-1-yl)-2-methoxybenzonitrile(1018326-11-8)

Safety Data

• Hazardous Substances Data: 1018326-11-8(Hazardous Substances Data)

Upstream product

• 330793-38-9 4-bromo-2-methoxybenzonitrile 
• 1018326-01-6 2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)-1-(piperidin-4-yl)ethanol 
• 301221-79-4 4-Bromoacetyl-1-(t-butoxycarbonyl)piperidine 
• 206989-61-9 4-acetyl-1-(t-butoxycarbonyl)piperidine 
• 139290-70-3 tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 139102-34-4 methyl 4-bromo-2-methoxybenzoate 
• 1018325-99-9 tert-butyl 4-(2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperidine-1-carboxylate 
• 812667-44-0 4-bromo-2-methoxybenzamide 

Relevant articles and documents

CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of MIP-1α of formula (I), or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n, A, T, R1, R2 and R8, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.